换一批Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel.
第一作者：
Jean-Pierre,Droz
第一单位：
aDepartment of Medical Oncology, Centre Léon-Bérard, Claude Bernard Lyon-1 University, Lyon bMedical Oncology Department, Georges Pompidou European Hospital (HEGP), Paris cDepartment of Medical Oncology, Institut Claudius Regaud, Toulouse dBoehringer Ingelheim France S.A.S, Reims, France eBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
作者：
医学主题词
腺癌(Adenocarcinoma);老年人(Aged);老年人, 80以上(Aged, 80 and over);抗肿瘤药(Antineoplastic Agents);疾病恶化(Disease Progression);无病生存(Disease-Free Survival);人类(Humans);吲哚类(Indoles);男(雄)性(Male);中年人(Middle Aged);紫杉烷类(Taxoids);微管蛋白调节因子(Tubulin Modulators)
DOI
10.1097/CAD.0000000000000131
PMID
24849708
发布时间
2018-12-02
- 浏览24
Anti-cancer drugs
1081-8页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
